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1. Introduction
The task of researching and developing novel therapeutic agents,
especially in the therapeutic area of central nervous system (CNS)
drugs, remains an expensive, uncertain, time-consuming, competitive,
and inefficient enterprise (Safavi et al., 2016). These challenges result
in a very high failure rate of CNS drug development programs and pose
continuous challenges for all stakeholders involved in drug discovery,
including regulators and payers alike.
One of the key issues facing current regulatory processes for CNS
therapies is the complete or partial lack of tractability among current
paradigms. Such disagreement is likely due to a lack of understanding
in several areas: disease pathophysiology; disparities, or low in-
formative value, between animal models and the target disease; lack of
translatability of results from healthy individuals to patients; hetero-
geneous patient populations and complex diagnostic entities; and
complications (e.g. treatment discontinuation, death) that may occur
during clinical trials. Heterogeneity between patients may result in
differences in response, tolerability and/or adherence to a particular
treatment, both in clinical trials and real-world settings. These factors
subsequently impact upon the design of clinical trials that represent the
real-life population of patients (with their inclusion and exclusion cri-
teria), the choice of informative comparators, the use of validated
endpoints, tools and scales, and therefore the ability of regulators to
properly evaluate novel therapies to the point of approval.
Regulatory decisions are currently based upon the results of
randomized controlled trials (RCTs), within which treatment conditions
are highly optimized and the patient population is strictly controlled.
Consequently, RCTs may lack external validity, thus creating an effi-
cacy-effectiveness gap, whereby drugs perform well in clinical trials
(efficacy) but fail to do so in clinical practice (effectiveness) (Eichler
et al., 2011). Although they will never be relevant to all patients and
clinical settings, RCTs should be designed and reported in such a way
that the target population is clearly identified (Rothwell, 2006; Thorpe
et al., 2009). Some approaches, with the potential to reduce attrition
rates, have recently been proposed; furthermore, the judicious use of
clinically qualified predictive biomarkers holds great promise for fur-
ther development of therapeutic targets, improved survival, and ulti-
mately personalized medicine (Safavi et al., 2016). These biomarkers
may help to identify specific populations that could benefit from a
treatment within an RCT and clinical practice. For instance, measures
such as attenuated mismatch negativity (Koola, 2018; Naatanen et al.,
2016), brain intrinsic functional networks (Du et al., 2018), and
structural network alterations (Padula et al., 2017) all hold promise for
tracking individual patient progress, disease progression or modifica-
tion, and pharmacological mechanisms of action. Biomarkers that can
justify label claims for both registration and reimbursement are being
pursued with particular vigor.
This article aims to provide an overview of the regulatory and policy
issues relating to the treatment of CNS disorders, with a focus on at-
tenuated psychosis syndrome (APS) and schizophrenia.
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2. Emerging regulatory trends
“Evidence versus access,” a conundrum often faced by drug reg-
ulators, refers to the delicate balance between encouraging rapid pa-
tient access to promising therapies, whilst ensuring that there is ade-
quate evidence regarding the benefits and harms of the therapy at the
time of market authorization (Eichler et al., 2015; Woodcock, 2012).
Increasingly well informed and better organized patient advocacy
groups have been a driving force behind calls for drug development and
market access to benefit patients in the here and now (Eichler et al.,
2015). To facilitate such rapid access, however, payers (and sometimes
patients) must first consider any uncertainties regarding net benefit
alongside potential financial costs and the availability of alternate
treatment options (Eichler et al., 2015). In response, a number of
flexible licensing pathways, including accelerated approval (USA) and
conditional marketing authorization/approval (EU and Japan), have
been implemented or are being explored by legislators and regulatory
agencies (Baird et al., 2014; Eichler et al., 2015). Such approaches are
pertinent for situations whereby immediate availability of the therapy
would generate public health benefits that outweigh the inherent risks
of the time required for additional data to be collected (Commission
Regulation, 2006). Healthcare payers have responded by adopting a
range of innovative reimbursement approaches, termed “managed
entry agreements (MEAs)”. MEAs help ensure rapid access to novel
health technologies, whilst maintaining value and developing real-
world effectiveness and valued outcomes, such as avoided costs, which
can provide additional information on the relative effectiveness as-
sessment of new products (Henshall and Schuller, 2013; Klemp et al.,
2011; Pavlovic et al., 2014; Stafinski et al., 2011). Considering the in-
creased pressure to facilitate rapid access to potentially beneficial new
therapies, regulators now seem to be more open to the discussion and
implementation of revisions that would aid improvement of current
regulatory processes. For example, discussions leading to a better un-
derstanding of patient subgroup stratification within complex multi-
factorial diseases could enhance study design and outcomes during late-
stage drug development. Furthermore, choice of endpoints and how
they are reported have a major impact on the relative effectiveness
assessment (REA) of pharmaceuticals, a component of health tech-
nology assessment (HTA) (Pavlovic et al., 2014). The EUnetHTA
guidelines on endpoints for REA state that the choice of all endpoints
should depend upon the particular disease, population, treatment, and
decision context (Pavlovic et al., 2014). Long-term endpoints are pre-
ferred wherever adequate and feasible; however, short-term endpoints
are acceptable for acute conditions; surrogate endpoints can also be
used when validated against the final outcome of interest (Pavlovic
et al., 2014).
There is also an emerging trend for early and ongoing dialogue
between regulators and payers to avoid the issues seen with anti-he-
patitis C (HCV) (AASLD-IDSA, 2017) and anti-low-density lipoprotein
(LDL) monoclonal antibodies (Baum, 2017; Baum et al., 2017), in
which restrictive criteria for reimbursement have limited their use in
clinical practice, despite approval in a broad patient population. Dis-
sonance between the development of novel therapies and the lack of
creativity demonstrated during manufacturer-payer negotiations, may
contribute to regulators authorizing a much larger patient population to
be treated than payers are accepting for reimbursement. For instance,
sofosbuvir, indicated for the treatment of chronic HCV mono-infection
and HCV/human immunodeficiency virus-1 coinfection as part of a
combination regimen, was limited to patients with advanced fibrosis or
cirrhosis by the majority of payers worldwide (Barua et al., 2015).
Further interesting examples include the anti-proprotein convertase
subtilisin/kexin type 9 (PCSK9) monoclonal antibodies evolocumab and
alirocumab, which had US Food and Drug Administration (FDA) fast-
track approval (Toklu et al., 2016). These drugs were approved as ad-
juncts to diet and maximally tolerated statin therapy for patients with
familial hypercholesterolemia or clinical atherosclerotic cardiovascular
disease, who required a greater reduction in LDL cholesterol levels.
Despite the study of PCSK9 inhibitors for use in other patient sub-
groups, such as statin-intolerant patients in the Goal Achievement After
Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
(GAUSS-3) trial, these agents are not currently approved worldwide for
other indications (Nissen et al., 2016), mainly for reimbursement rea-
sons. These examples illustrate that even successful therapies with
previously unattainable clinical effectiveness and statistically sig-
nificant efficacy versus comparator, fail to achieve reimbursement for
all patients due to sustainability and lack of satisfactory negotiation
models. In other cases, regulators appear to have been obliged to ap-
prove drugs for use in much less well-defined populations than those in
clinical trials, leading to increased variability in drug response and
decreased real-world effectiveness (Eichler et al., 2011). The Massa-
chusetts Institute of Technology's NEW Drug ParadlGmS (NEWDIGS)
initiative is a multi-stakeholder collaboration, within a neutral “safe
haven” environment, that aims to define what an adaptive development
and licensing program to enable timely availability of innovative
medicines might look like (Baird, 2013). Importantly, the initiative
suggests that regulatory change will not be achieved by regulators
alone, and that a safe environment for such discussions will be required
for stakeholders to align regarding benefit-risk tradeoffs. For some
treatments, such as gene therapy, there may also be some uncertainty
about long-term durability of response, even at the time of approval,
because this cannot be fully assessed in a clinical trial (Gottlieb, 2018).
Indeed, the NEWDIGS FoCUS (Financing and Reimbursement of Cures
in the USA) consortium suggest that precision financing approaches
may be required for such durable, perhaps lifetime, therapies that incur
high upfront reimbursement costs (MIT NEWDIGS FoCUS Project,
2017).
Regulators are also becoming more amenable to discussions re-
garding the approval of potential new target populations and indica-
tions. Patient populations in RCTs could be enriched according to the
presence of biomarkers (genetic and/or phenotypic), improving the
ability of regulators to license drugs for specific populations and po-
tentially leading to improved efficacy and/or safety (Arneric et al.,
2018; Eichler et al., 2011; EMA, 2010). Indeed, regulatory (FDA,
2018c) and clinical (Mobasheri et al., 2019) perspectives from other
heterogeneous, multifaceted diseases with multiple causes concur that
biomarkers may be employed as tools for patient stratification in clin-
ical trials, and for more rational and targeted drug development.
Such treatments have the considerable benefit of potentially being
able to modify disease progression. However, these unique approaches
require researchers to apply new methodologies, such as novel bio-
marker strategies and unique clinical trial designs, and to consider the
application of data collected from trial designs that are new to them.
The key example for the purpose of this article is the prevention of
first-episode psychosis in patients with APS via early intervention.
This strategy is currently being investigated with the novel
phosphodiesterase 9 inhibitor BI 409306 (Keefe et al., 2017). These
preventative strategies are also being applied to Alzheimer's disease
(AD), where research has identified the APOE and TOMM40 genetic loci
as associated with the age of AD onset (Crenshaw et al., 2013). While
Takeda and Zinfandel discontinued the pioglitazone program using the
TOMM40 biomarker as a treatment criterion, putatively due to in-
adequate treatment effect (Takeda, 2018), other preventative trials are
underway. Meanwhile, Biogen has initiated Phase I studies for the use
of aducanumab in patients with prodromal or mild AD (NCT01677572).
Moreover, regulators have proposed the use of biomarkers as tools to
improve the diagnosis specificity of AD and to predict conversion from
a specific amnestic disorder to full dementia status over a relatively
short time period (≤2 years) (Isaac et al., 2011). Current prospective
data consistently demonstrate that for patients with mild cognitive
impairment, per the Peterson Criteria (less specific for AD than the
Dubois Criteria), a positive cerebral spinal fluid (CSF) tau/Aβ1–42 bio-
marker ratio is predictive of conversion to dementia within the next
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2–3 years. The relative risk for dementia is still uncertain; nevertheless,
it is known to be more frequent in patients with a positive CSF bio-
marker ratio than those with a negative CSF biomarker ratio (Isaac
et al., 2011).
These strategies are likely to open debate on the differences be-
tween disease modification and progression, and whether demon-
strating disease-modifying activity is truly a requirement. Discussion
around these paradigms should also consider the correlation between
improvement in symptoms/functioning, normalization of the under-
lying biological mechanism of disease, and choice of biomarkers and
trial design while considering differences between European, US, and
Asian regulatory requirements. Challenges associated with disease
modification must also be considered, such as trial duration, sample/
effect size, the non-inferiority margin, patient withdrawal, and the
subsequent effects on randomization and missing data.
3. Continuum versus spectrum disorders
AD, Parkinson's disease (PD), and many other neuropsychiatric
disorders can be considered as progressive, or continuum, neurological
disorders that follow a pattern of increasing severity over time (EMA,
2012; EMA, 2018). The shift toward a desire for early treatment of PD,
for instance, has triggered a vast amount of research into the use of
biomarkers with high positive predictive value for early population
identification (EMA, 2012; Noyce et al., 2016). Regarding AD, EMA
representatives consider pharmacological interventions directed to
suspected pathophysiological mechanisms underlying AD at a pre-
symptomatic stage to be a reasonable strategy for prevention (EMA,
2018). Similarly, FDA representatives consider patients with Stage 1 AD
(no symptoms) a valid target, because in their view intervention should
start as early as possible (FDA, 2018b). As such, biomarkers are gaining
increasing interest as a potential basis for the accelerated assessment of
such conditions.
Psychiatric illnesses are also being reconceptualized, but as trans-
diagnostic entities such as with the Research Domain Criteria approach
(Cuthbert and Insel, 2013) that focuses on the underlying biology that
manifests as specific behavior and experience. Classic diagnostic enti-
ties are also under re-examination as more genetic and biological data
come to light. For example, recent opinion suggests that schizophrenia
should undergo a reconceptualization of breadth to become part of the
psychotic spectrum (Fig. 1) (Guloksuz and Van Os, 2018), similar to
what has been established for autism spectrum disorder. This perspec-
tive would consider the clinical manifestations of schizophrenia, schi-
zoaffective disorder, and bipolar disorder, including affective and non-
affective symptoms and the five symptom dimensions (positive and
negative symptoms, mania, depression and disorganization) as part of
the same spectrum of illness (Guloksuz and Van Os, 2018). We agree
with this approach, which will pave the way for future conceptualiza-
tion (Guloksuz and Van Os, 2018) and identification of the key trans-
diagnostic factors that limit function and produce suffering.
4. Regulatory issues: schizophrenia and APS
The reconceptualization of schizophrenia as a part of a spectrum of
psychosis that includes APS raises further regulatory and reimburse-
ment issues. APS could represent an early manifestation of schizo-
phrenia or other psychotic disorders, with 26% of such individuals
converting to psychosis within 38months (Fusar-Poli et al., 2015). APS
symptoms may also remit in ~50% of non-converters (Cannon, in press;
Lam et al., 2018). Following remission, these participants may not be
distinguishable from the general population. The APS population poses
two challenges: (1) from a clinical perspective, it may be unethical and
unjustifiable to treat these individuals and (2) payers may not re-
imburse treatment for such individuals. Additionally, transitory, en-
during, and progressing forms of APS are difficult to differentiate from
one another based solely on clinical observation. The development of
new biomarkers could contribute to a more accurate differentiation and
prediction of how APS will progress over time.
As the focus on prodromal conditions in regulated trials burgeons,
new methods have been developed to understand the novel emergent
data. When it comes to APS, the possibility of intercurrent clinical
events that occur after treatment randomization is of particular re-
levance. These events include the occurrence of an index psychotic
episode that would call for the use of a rescue medication, use of a
medication prohibited by the protocol or subsequent line of therapy,
discontinuation of treatment, treatment switching, or a terminal event
such as death. These events will either preclude observation of the
variable or affect its interpretation.
One approach for regulators trying to address these issues is the use
and definition of estimands in clinical trials. This is reflected by the
development of an addendum of the International Council for
Harmonization of Technical Requirements for Pharmaceuticals for
Human Use (ICH) E9, which covers estimands and sensitivity analyses
in clinical trials (ICH R9[R1]) (ICH, 2017). ICH R9 (R1) attempts to
better define what is perhaps the most important question for drug
development and licensing, which seems to be of relevance in the case
of APS: the quantification of treatment effects. In other terms, the use of
estimands that define how a treatment outcome compares with the
outcome that would have occurred in the same patients under different
treatment conditions. An estimand considers whether values of the
variable after an intercurrent event (that occurs after treatment initia-
tion and precludes the observation or affects the interpretation of the
variable of interest) are relevant. It also considers how to account for
the (possibly treatment-related) occurrence or non-occurrence of the
event itself. More formally, an estimand provides a detailed definition
of what needs to be estimated in order to answer a specific trial ob-
jective. Estimations within clinical trials include: the population of in-
terest (the patients who are eligible for inclusion); the endpoint of in-
terest (measurements taken and the timepoint or period of interest); the
specification of how to account for intercurrent events and whether
these are of interest to the endpoint (early discontinuation, rescue
medication, death); and the population-level summary measure (how
are comparisons between treatment conditions summarized) (ICH,
2017).
These regulatory guidelines may provide great benefit to clinical
trials testing the safety and efficacy of treatments for prodromal con-
ditions. According to the guidelines, a stratum of the target population
may be of interest, defined in terms of a potential intercurrent event; for
example, the stratum of patients who would adhere to the treatment.
With regards to APS specifically, it could be argued that because pa-
tients have high rates of spontaneous remission and non-conversion,
they may be poorly adherent. On the other hand, patients may be
suffering and would therefore derive value from a relieving treatment
to manage any symptoms and possibly assist their daily functioning. In
any case, these patients are highly deserving of treatment, and the key
outcome measures for APS may consist of quantities related to clinical
outcomes (e.g. time to first episode, hospitalization required, duration
of hospitalization). These variables may also incorporate intercurrent
events such as discontinuation of treatment, treatment taken prior to
discontinuation and treatment based on composites (e.g. treatment
failure defined as non-response or treatment discontinuation due to lack
of efficacy and/or safety issues). Since intercurrent events can present
in multiple forms, and thus affect interpretation of the variable of in-
terest, it will be necessary to specify how to account for potential in-
tercurrent events in a way that reflects the particular scientific question.
For example, if a patient takes rescue medication in addition to the
treatment of interest, the scores for the selected endpoints will reflect
the combined effect of the treatment and the rescue medication. If a
patient discontinues treatment because of toxicity, again the scores for
the selected endpoints will reflect the lack of effect of the treatment
when it is not taken.
Currently, there are no approved medications for APS, and there is
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no established regulatory standard for the conduct of clinical trials in
this area. Research into the accurate and sensitive inclusion of in-
dividuals within clinical trials, and the conduct of such trials within the
global regulatory environment, requires further consideration. Indeed,
during the design of novel drug trials that will enroll patients at high
risk of conversion to psychosis, several factors must be carefully con-
sidered. Firstly, treatment response should be monitored according to
positive, negative, and cognitive symptom scales that have regulatory
approval. The measurement of such symptoms should continue for a
sufficient number of months/years, dictated by the natural history of
the disorder under study, in a sufficient number of patients, to enable
significant changes in a number of predetermined measurable variables
(i.e. time to first episode, hospitalization required, duration of hospi-
talization) to be observed. For instance, should hospitalization be
considered as an outcome for a study, the sample size should be large
enough to support the claim that hospitalization slows (or even modi-
fies) the progression to psychosis. Secondly, it should be considered
that, although the scientific question of interest (treatment versus pla-
cebo) may be best addressed via an RCT, such trials are not always free
from confounding and selection bias. Of course, RCTs are expected to be
free from baseline confounding bias; however, not necessarily from
post-randomization confounding and selection bias. Finally, it must also
be considered that high-risk patients may not be able to adhere to
treatment over an extended period of time.
5. Future considerations for APS trials and treatment
One of the most important regulatory issues in the evolution of
medicine toward treatment of a prodromal state is precise patient
identification. The early detection of subtle changes based on APS
symptoms such as unusual perception, thought and suspiciousness,
cognitive performance on symbol coding and verbal memory, changes
in global functioning, and digital speech analytics may help to limit the
number of false positive cases included in trials (Bedi et al., 2015;
Cannon et al., 2016). Importantly, some patients with high-risk symp-
toms may never convert to psychosis; however, they may still experi-
ence attenuated psychotic symptoms for many years, if not decades.
This group of non-remitters who do not convert comprises a large
proportion of all patients with APS, and they have considerable mor-
bidity. Moreover, high risk for psychosis has been shown to be high risk
for other psychiatric issues; therefore, identification of this patient
population is very important. Criteria to identify this group of patients
remain poorly defined, but should aim to describe a specific time period
after which non-conversion is confirmed (this time period may be of
considerable duration). It may be a legitimate strategy to treat patients
with these APS symptoms using a similar approach to that used in the
treatment of negative symptoms or cognitive deficits in people with
schizophrenia (but without the need to manage psychosis). The aim
would be to reduce their suffering and to act on specific treatment
targets, such as non-remission, negative symptoms, cognitive deficits,
functional capacity, and social competence. Thus, a simple dichotomy
of conversion to psychosis versus non-conversion may not account for
the benefits of symptom reduction to these patients.
Biomarkers are emerging as potentially being of particular interest
for the identification of patients with prodromal disorders who would
benefit from specific interventions; however, this strategy is hampered
by the complexity of schizophrenia and the diverse range of genetic and
environmental factors that are associated with the condition (Goff et al.,
2016). Ideally, to guide treatment, regulators would prefer biomarkers
linked to a drug mechanism of action and disease neurobiology to allow
a disease-modifying claim within the product label. Furthermore, the
EMA has recently highlighted a need for the co-development of bio-
markers alongside corresponding assays that can be successfully tran-
sitioned into clinical practice (EMA, 2017). Additional regulatory hur-
dles associated with prodromal states may include the measurement of
positive and negative predictive values for biomarkers, the sustain-
ability of time to event analyses and clinical meaningfulness of the
event, and the use of surrogate endpoints if patients are not followed for
long enough.
Digital medicine and bio-behavioral markers have the potential to
identify and track patients (Dagum, 2018; Insel, 2017), and hold great
promise for individuals with prodromal psychosis. For example, Bedi
et al., describe a novel combination of automated semantic and syn-
tactic speech analyses able to accurately predict conversion to psychosis
in a clinical high-risk cohort; substantial additional validation is,
however, required (Bedi et al., 2015). Digital tools that can be used on
Threshold value
of liability
Affected
individuals
Broad
phenotype
Mean liability in
the general
population
Mean liability in
the siblings of
affected individuals
Fig. 1. The psychotic spectrum
S. Guloksuz and J. van Os. The slow death of the concept of schizophrenia and the painful birth of the psychosis spectrum. Psychological Medicine, 2018, 48, 2,
229–244, reproduced with permission.
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smartphones or tablets are of particular interest (FDA, 2018a). Such
applications would allow the active measurement of cognitive function
(i.e. symbol coding test) (Atkins et al., 2017) and functional capacity
(Keefe et al., 2016), with the possibility of an integrated reward system
to promote adherence, in addition to the more passive measurement of
movement and social functioning via global positioning system (GPS).
As is true for any measure, several basic psychometric and testing
considerations must also be applied to digital biomarkers, including
reliability, validity, practicality, and translatability. Validation and
certification of digital measures will be a necessity for regulators and
payers, and they will value the ability of such tools to transition from
clinical trials into clinical practice. The resulting strength of such evi-
dence could be used to direct reimbursement criteria. Of note, three
areas of technology currently in development will be valuable for the
detection and medium/long-term follow-up of patients with APS: (1)
wearable sensors for activity monitoring (broadly speaking); (2) pattern
recognition (speech, movement, behavioral); and (3) human machine
interfaces capable of handling interactions between humans and de-
vices, such as smartphones.
However, there are several challenges associated with the use of
these new technologies. In particular: selecting the appropriate device
for a particular endpoint; choice of device features; choice of metrics to
assess sensitivity, reliability, and clinical relevance; applicability to
different populations/countries; requirement for internet connectivity
via Wi-Fi or Bluetooth; patient privacy, experience, training, and ad-
herence; usability of the technology; and specific data challenges, such
as volume and continuous data flow, making it difficult to determine a
defined variable or endpoint. Furthermore, when capturing data from
such digital devices there are the additional challenges of missing and/
or unrealistic values, and the need to prepare the data for regulatory
submission. Importantly, the Clinical Trials Transformation Initiative
recommendations for the use of mobile technologies state that: “Any
test, tool, or instrument used for data collection in a clinical trial should
meet acceptable feasibility and performance characteristics such as
accuracy, precision, and consistency of measurements over time, and
uniformity of measurements across mobile technologies. When mobile
technologies are used for data capture, they should also meet relevant
technical performance specifications that relate to their ability to re-
liably capture, process, store, and transfer the valid data to satisfy the
needs of the trial. Sponsors should have access to data quantifying the
accuracy, precision, consistency, and uniformity of the technologies.
This information would reasonably be provided by the mobile tech-
nology manufacturer.”
6. Conclusions
The evolving reconceptualization of schizophrenia as a psychotic
spectrum disorder, along with increased focus on the prodromal stages
of the disease, is placing increasing pressure on the regulatory system.
APS represents one of the earliest manifestations of the psychosis
spectrum, and regulators are now realizing the importance of therapies
that target these initial stages. The subsequent interest in biomarkers
for the identification of patients with prodromal CNS disease is ex-
tremely challenging due to the various molecular and environmental
complexities involved. Moving forward, translational science should be
applied to regulatory concepts and measures, with regulatory guide-
lines followed for the certification of such measures. Finally, digital
technologies that enable active measurement of key endpoints in both
clinical trials and real-world settings will shortly be available, paving
the way for a new era in patient identification and monitoring.
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